National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist or have medical contraindications to such therapies


Rapid Review

Commenced Completed Outcome
28/11/2016 11/01/2017 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.

 The HSE has approved reimbursement following confidential price negotiations November 2017